United States Embolic Protection Device Market Report by Product, Application, Material, End-User, States and Company Analysis, 2026-2034

United States Embolic Protection Device Market Size and Forecast 2026-2034

United States Embolic Protection Device Market is expected to reach US$ 0.7 Billion by 2034 from US$ 0.38 Billion in 2025, with a CAGR of 6.96% from 2026 to 2034. The U.S. embolic protection device industry is driven by rising cardiovascular disease prevalence, increasing interventional procedures, aging populations, demand for stroke-risk reduction, technological improvements in filter systems, minimally invasive treatment adoption, and expanding use across coronary and carotid interventions.

United States Embolic Protection Device Industry Overview

The United States embolic protection device industry is an important segment of the interventional cardiovascular device market, supporting procedures where manipulation of atherosclerotic or thrombotic material can release debris into the bloodstream. These devices are designed to capture, divert, or prevent embolic material from reaching critical downstream vessels during selected vascular interventions. The FDA classifies temporary carotid embolic-capture systems as Class II percutaneous catheter devices, with applications including angioplasty and stenting procedures. FDA guidance specifically addresses coronary and carotid embolic protection devices used during interventions involving carotid arteries and saphenous vein bypass grafts.

Demand is closely linked to the country's substantial cardiovascular disease burden and the continued use of minimally invasive interventions. The CDC identifies coronary artery disease as the most common type of heart disease in the United States, while 5.0% of U.S. adults had ever been diagnosed with coronary heart disease in 2024. An aging population further supports procedural demand because cardiovascular disease and complex vascular conditions become more prevalent with age. The market encompasses distal filter devices, distal and proximal occlusion systems, and integrated protection technologies used in coronary, carotid, and other vascular procedures.

The competitive environment combines established medical-device manufacturers with companies developing integrated stent-and-protection systems and next-generation embolic management technologies. Product development is increasingly focused on improving deliverability, filter capture efficiency, vessel compatibility, deployment accuracy, and procedural simplicity. At the same time, clinical evidence continues to influence utilization patterns. A 2025 study examining distal filter-wire embolic protection during saphenous-vein-graft PCI reported no improvement in short-term major adverse cardiovascular and cerebrovascular events or longer-term survival, illustrating the importance of evidence-based device selection and physician preference. These dynamics are shaping future adoption across hospitals, specialty cardiovascular centers, and ambulatory surgical settings.

Key Factors Accelerating Market Development

Increasing Cardiovascular Disease Burden

The prevalence of cardiovascular disease provides a fundamental demand base for embolic protection technologies. Coronary artery disease is the most common form of heart disease in the United States, and the CDC reported that 5.0% of U.S. adults had ever been diagnosed with coronary heart disease in 2024.

As cardiovascular disease progresses, some patients require invasive procedures including PCI, carotid interventions, structural-heart procedures, and other vascular treatments. Certain interventions can disturb plaque or thrombotic material, creating a potential risk of distal embolization. This environment supports the use of technologies designed to capture or prevent embolic debris during selected procedures. The aging U.S. population is also important because older adults generally experience greater cardiovascular disease burden and may undergo more complex interventions.

The market therefore benefits from the continued development of minimally invasive cardiovascular procedures. Device manufacturers are focusing on systems that can provide protection without substantially increasing procedural complexity. Growth in cardiovascular intervention volumes, combined with the need to improve procedural safety, is expected to sustain opportunities for embolic protection technologies.

Expansion of Minimally Invasive Vascular Interventions

Healthcare delivery in the United States continues to emphasize less invasive treatment approaches that can reduce recovery time and hospitalization requirements. PCI, carotid stenting, structural-heart interventions, and other catheter-based procedures have expanded the role of specialized intravascular devices. Embolic protection systems complement this trend by addressing procedural risks associated with manipulating diseased vessels. Their ability to capture or divert debris can be particularly relevant during interventions involving heavily diseased vessels or bypass grafts.

FDA's regulatory framework specifically recognizes coronary and carotid embolic protection devices and provides guidance for their premarket evaluation. The availability of established regulatory pathways can encourage manufacturers to continue developing improved designs. Technological advances are also making devices more deliverable through increasingly sophisticated catheter systems. Improvements in wire design, filter construction, vessel tracking, deployment mechanisms, and retrieval can support procedural efficiency.

As interventional cardiology and vascular surgery increasingly adopt catheter-based techniques, manufacturers that can demonstrate clinical utility, procedural simplicity, and favorable safety profiles may gain competitive advantages.

Device Innovation and Integrated Protection Systems

Technological innovation remains a major growth factor. Traditional embolic protection devices have generally relied on filters or occlusion mechanisms, but the industry is moving toward more sophisticated and integrated approaches.

FDA describes embolic capture systems as temporary percutaneous catheters that can use an embolic capture filter or occlusion balloon positioned relative to the lesion. This flexibility allows manufacturers to develop different protection approaches depending on anatomy and procedure. Recent developments such as the Neuroguard IEP integrated carotid system demonstrate efforts to combine stenting, post-dilatation, and embolic protection in a single platform. Such integration may reduce the number of devices required during a procedure and potentially simplify workflow.

Future innovation is likely to emphasize smaller profiles, improved vessel compatibility, easier deployment and retrieval, better debris capture, and integration with imaging and navigation technologies. Manufacturers capable of combining protection with procedural efficiency and strong clinical evidence are positioned to compete effectively in the U.S. market.

Major Industry Challenges

Uncertain Clinical Utilization and Evidence Requirements

One of the principal challenges is demonstrating clear clinical benefit across different procedures and patient populations. While embolic protection is intended to reduce the risk associated with embolic debris, clinical outcomes can vary according to anatomy, lesion characteristics, procedural technique, device selection, and patient risk.

Recent evidence has questioned the routine use of distal filter-wire protection during contemporary saphenous-vein-graft PCI. The 2025 study found no improvement in short-term MACCE or longer-term survival among the studied population. Such findings can influence physician preferences and hospital purchasing decisions. Manufacturers therefore need to demonstrate meaningful clinical value through robust studies and real-world evidence.

The challenge is particularly important because cardiovascular specialists increasingly evaluate technologies based on outcomes, procedural efficiency, total cost, and patient selection. Devices that add procedural expense or complexity without clearly demonstrated benefits may face slower adoption.

Regulatory, Procedural, and Cost Pressures

Medical-device manufacturers face substantial regulatory requirements before products can enter the U.S. market. FDA guidance establishes specific considerations for coronary and carotid embolic protection devices, including clinical and non-clinical evaluations and labelling.

Companies must therefore invest in engineering, testing, clinical evidence, regulatory submissions, manufacturing controls, quality systems, and post-market surveillance. These requirements increase development timelines and costs. Hospitals also face pressure to control procedural expenditures. A new embolic protection device must compete with established products while demonstrating sufficient value to justify adoption.

Procedural complexity can present another barrier. Devices that require additional steps, specialized training, or longer procedure times may encounter resistance compared with integrated or simpler alternatives. Consequently, manufacturers must balance protection performance with ease of use, cost-effectiveness, physician familiarity, and compatibility with existing interventional workflows.

California Embolic Protection Device Market

California represents a major U.S. market for embolic protection devices because of its large population, advanced healthcare infrastructure, and concentration of academic medical centers and cardiovascular specialists. Major metropolitan regions support sophisticated interventional cardiology and vascular programs, creating demand for coronary and carotid technologies. The state also has extensive hospital networks and specialty cardiovascular centers capable of performing complex catheter-based interventions. Embolic protection demand is influenced by coronary artery disease, carotid disease, aging populations, and the continued adoption of minimally invasive procedures. California's strong medical-technology ecosystem further supports clinical research, device evaluation, and adoption of innovative cardiovascular technologies. Hospitals are increasingly interested in devices that combine clinical effectiveness with procedural efficiency and cost management. Integrated embolic protection systems, improved delivery platforms, and disposable technologies may therefore gain attention as healthcare providers seek to optimize interventional workflows and patient outcomes.

Texas Embolic Protection Device Market

Texas is an important market for embolic protection technologies because of its large population, extensive hospital network, and established cardiovascular intervention infrastructure. Houston, Dallas-Fort Worth, San Antonio, and Austin contain major medical institutions with advanced cardiology and vascular programs. Demand is supported by coronary artery disease, carotid interventions, aging populations, and continued adoption of catheter-based procedures. Texas also has a combination of large metropolitan centers and geographically dispersed communities, creating opportunities for regional cardiovascular centers and specialized hospitals. Device suppliers compete through physician education, clinical evidence, product availability, and relationships with hospitals and healthcare systems. Cost considerations remain important as providers seek technologies that improve procedural outcomes without adding unnecessary expenditure. The state's growing healthcare infrastructure can support adoption of next-generation embolic protection platforms, particularly devices that offer easier deployment, improved navigation, and integrated functionality.

New York Embolic Protection Device Market

New York represents a sophisticated market for embolic protection devices due to its concentration of major hospitals, academic medical centers, cardiovascular specialists, and high-volume interventional programs. New York City serves as a major center for complex cardiovascular procedures and clinical research, supporting demand for advanced vascular technologies. Embolic protection devices may be used in selected coronary, carotid, and other vascular interventions where clinicians consider embolic risk significant. Hospitals increasingly evaluate devices based on clinical evidence, procedural efficiency, safety, and economic value. New York's strong research environment also supports clinical studies and adoption of emerging technologies. At the same time, healthcare organizations face pressure to manage costs and standardize purchasing across large hospital networks. Manufacturers that provide robust clinical evidence, physician training, reliable supply, and integration with established catheter-based workflows are therefore better positioned to expand within the state's competitive cardiovascular device market.

Florida Embolic Protection Device Market

Florida offers substantial potential for embolic protection devices due to its large older-adult population and significant demand for cardiovascular healthcare. Aging is closely associated with increased cardiovascular disease burden, creating a large patient population requiring coronary, carotid, and other vascular interventions. The state has extensive hospital networks, specialty cardiovascular centers, outpatient facilities, and ambulatory surgical infrastructure. Demand for embolic protection technologies is influenced by the number and complexity of interventional procedures performed across these settings. Florida's retirement communities also contribute to sustained demand for cardiac and vascular healthcare services. Healthcare providers increasingly emphasize minimally invasive interventions and improved procedural safety. Manufacturers can benefit from focusing on physician education, clinical evidence, and devices that simplify deployment while maintaining effective embolic capture. Portable, disposable, and integrated technologies may also gain traction where they can support efficient procedural workflows and reduce equipment-management requirements.

Distal Filter Devices Market

Distal filter devices are an established category within the U.S. embolic protection market and are designed to capture debris downstream from the treatment site while allowing continued blood flow. These systems typically incorporate a filter mounted on a guidewire that is positioned beyond the lesion before intervention. Their design makes them particularly relevant to procedures where plaque or thrombotic material may become dislodged. FDA records identify SpiderFX as a temporary coronary saphenous-vein-bypass-graft embolic protection device and classify the technology as a Class II cardiovascular device. The segment faces growing competition from alternative protection approaches and questions regarding routine utilization in certain procedures. Nevertheless, distal filters remain important because of established physician familiarity, procedural experience, and availability across coronary interventions. Future development is likely to focus on improved crossing profiles, enhanced capture efficiency, better retrieval, and simplified deployment.

Coronary Artery Treatment Market

The coronary artery treatment segment represents an important application area for embolic protection technologies because coronary interventions can involve manipulation of plaque and thrombotic material. The United States has a substantial cardiovascular disease burden, with coronary artery disease identified by the CDC as the country's most common type of heart disease. Embolic protection may be considered in selected coronary procedures, particularly interventions involving diseased or previously bypassed vessels. The segment is influenced by PCI volumes, technological advances in stents and catheters, physician preferences, clinical evidence, and reimbursement. As coronary interventions become increasingly sophisticated, device manufacturers are developing systems that can be delivered through smaller profiles and integrated with existing procedural equipment. However, evidence regarding the incremental clinical benefit of routine embolic protection remains important. Future demand will therefore depend on identifying appropriate high-risk patients and demonstrating measurable improvements in procedural safety and outcomes.

Saphenous Vein Graft Intervention Market

Saphenous vein graft intervention has historically been one of the most recognized applications for embolic protection devices because older grafts may contain friable atherosclerotic material that can embolize during PCI. FDA specifically recognizes temporary coronary saphenous-vein bypass-graft embolic protection as a Class II device category. However, utilization is influenced by contemporary clinical evidence. A 2025 study evaluating distal filter-wire protection in saphenous-vein-graft PCI found no improvement in short-term MACCE or longer-term survival, potentially affecting routine adoption. Consequently, the segment is moving toward more selective use based on anatomy, lesion characteristics, thrombotic burden, physician judgment, and procedural risk. Manufacturers are expected to emphasize clinical evidence, ease of use, deliverability, and patient-selection strategies to maintain demand.

Disposable Devices Market

Disposable embolic protection devices represent an important component of the U.S. market because many catheter-based cardiovascular products are designed for single-patient use. Disposable systems help reduce concerns associated with reprocessing, cross-patient contamination, device integrity, and sterilization. They also provide manufacturers with recurring sales opportunities as cardiovascular procedures are performed across hospitals and specialty centers. The segment includes filters, guidewire-based systems, catheters, retrieval components, and integrated protection platforms. Hospitals evaluate disposable devices based on clinical performance, procedural convenience, acquisition cost, inventory requirements, and compatibility with existing equipment. Manufacturers are therefore developing lower-profile products that can simplify handling and improve procedural efficiency. The major challenge is cost containment because hospitals must manage the cumulative expense of single-use devices. Products that demonstrate measurable clinical value while reducing procedural time or complexity can gain an advantage in purchasing decisions.

Ambulatory Surgical Centers Market

Ambulatory surgical centers represent an emerging opportunity for embolic protection technologies as selected cardiovascular and vascular procedures increasingly move toward outpatient and lower-acuity settings. ASCs prioritize efficient workflows, shorter procedure times, predictable inventory requirements, and rapid patient turnover. These requirements favor embolic protection systems that are compact, easy to deploy, and compatible with existing catheter-based equipment. Adoption remains more limited than in large hospitals because complex cardiovascular procedures may require advanced imaging, surgical backup, intensive monitoring, and specialized teams. Nevertheless, improvements in minimally invasive technology and patient-selection protocols could expand the range of vascular procedures performed in outpatient environments. Disposable protection systems may be particularly attractive because they simplify sterilization and inventory management. Manufacturers targeting ASCs will need to demonstrate that their devices can maintain safety and procedural efficiency while fitting the economic and operational requirements of outpatient cardiovascular care.

Research Methodology of the United States Embolic Protection Device Market

1. Market Definition and Scope

• Define the United States Embolic Protection Device (EPD) Market by determining whether the study covers all embolic protection devices or focuses on cerebral and carotid applications.
• Include standalone filters, proximal protection systems, cerebral embolic protection devices used during transcatheter aortic valve replacement (TAVR), and other eligible coronary and peripheral applications within the agreed scope.
• Distinguish standalone devices from integrated protection systems to prevent double counting.
• Exclude unrelated vascular devices and procedures that do not involve embolic protection.

2. Bottom-Up Market Estimation

• Estimate market value by identifying eligible procedures, determining the percentage using EPDs, and multiplying the resulting device volume by the average selling price.
• Calculate each application separately because procedure volumes, adoption rates, and device prices vary by clinical setting.

Core Formula:

• U.S. EPD Market = Σ (Eligible Procedures × EPD Utilization Rate × Average Selling Price)

3. Carotid Embolic Protection Device Estimation

• Begin with the total number of carotid revascularization procedures performed in the United States.
• Separate carotid endarterectomy (CEA) from carotid artery stenting (CAS), as EPD use is primarily associated with carotid stenting.
• Estimate eligible CAS procedures, the proportion using an embolic protection device, and the corresponding device ASP.
• Use CMS coverage policies, ICD-10-PCS information, Medicare claims, hospital data, and clinical sources to validate procedure volumes and utilization assumptions.
• Treat the approximately 50,000 CAS procedures cited in the supplied methodology as a historical benchmark requiring verification against the latest available data.

Formula:

• Carotid EPD Market = CAS Procedures × EPD Adoption Rate × Average EPD Selling Price

4. TAVR-Related Cerebral Embolic Protection

• Estimate annual U.S. TAVR procedures and determine the percentage using cerebral embolic protection systems.
• Evaluate products such as the SENTINEL Cerebral Protection System and other eligible devices according to their indications and market availability.
• Establish adoption rates using hospital utilization, manufacturer disclosures, physician interviews, and available claims or clinical data.
• Do not assume that every TAVR procedure uses cerebral protection.

Formula:

• TAVR-Related EPD Market = Annual TAVR Procedures × Cerebral EPD Adoption Rate × Average Selling Price

• Forecast this segment separately because adoption and clinical practice may change differently from carotid applications.

5. EPD Utilization Rate Assessment

• Estimate utilization independently for carotid, TAVR, coronary, and peripheral procedures.
• Calculate utilization by dividing the number of eligible procedures using an EPD by the total number of eligible procedures.
• Validate utilization using hospital purchasing data, physician interviews, clinical studies, manufacturer shipment information, and claims-based procedure volumes where available.
• Account for differences in clinical protocols, physician preferences, device indications, reimbursement conditions, and hospital purchasing policies.

Formula:

• EPD Utilization Rate = Procedures Using EPD ÷ Total Eligible Procedures × 100

6. Average Selling Price Estimation

• Develop a product-level ASP database covering distal filters, proximal protection systems, cerebral protection devices, integrated systems, and other applicable product categories.
• Assess hospital acquisition prices, list prices, group purchasing organization discounts, distributor margins, contract pricing, and product-specific commercial terms.
• Distinguish manufacturer selling prices from hospital acquisition prices and reimbursement amounts.
• Calculate weighted ASPs using estimated unit sales and prices for each product category.

Formula:

• Weighted Average Selling Price = Total EPD Revenue ÷ Total EPD Units Sold

• Since most EPDs are single-use devices, annual procedure volumes and units consumed are important indicators of recurring product demand.

7. FDA Product-Level Database

• Build a database of FDA-cleared or approved EPD products and manufacturers using relevant FDA product classification, 510(k), PMA, and product documentation.
• Record manufacturer, product name, product code, clearance or approval date, intended use, eligible procedure, device technology, and U.S. commercial availability.
• Classify products by filter-based, balloon-based, proximal, distal, cerebral, and integrated protection technologies where applicable.
• Use FDA MAUDE reports as supplementary evidence for identifying marketed products and examining reported device-related events.
• Verify each product's current status and indication before including it in the market estimate; regulatory listings alone do not establish commercial sales.

8. CMS Claims-Based Market Validation

• Use CMS Medicare claims, physician fee schedule information, hospital inpatient and outpatient data, ambulatory surgical center information, and relevant ICD-10-PCS, CPT, and HCPCS classifications.
• Identify procedure volumes first and then estimate EPD utilization, as a procedure code may not separately identify whether an embolic protection device was used.
• Examine applicable coverage criteria, reimbursement arrangements, and proposed or implemented coding changes relevant to embolic protection.
• Supplement Medicare data with commercial claims, hospital purchasing records, and clinical information where available to capture procedures performed outside the Medicare population.
• Claims-Based Estimate = Eligible Procedure Volume × Estimated EPD Utilization × Average Selling Price

9. Manufacturer-Based Supply-Side Estimation

• Identify manufacturers and suppliers participating in the U.S. EPD market, including Abbott, Boston Scientific, Cordis, Medtronic, Silk Road Medical, Contego Medical, and other relevant specialized companies.
• Review annual reports, product portfolios, regulatory records, distribution information, hospital contracts, and product-level disclosures.
• Isolate EPD-related revenue from broader cardiovascular, vascular intervention, structural heart, and neurovascular product sales.
• For private companies or products with limited financial disclosures, estimate revenue using unit shipments, hospital purchasing data, product pricing, distribution records, and primary interviews.

Formula:

• U.S. EPD Revenue = Σ (Relevant U.S. EPD Units Sold × Average U.S. Selling Price)
• Adjust for exports, imports, inventory changes, and distributor sales where necessary to avoid counting the same device more than once.

10. Procedure-Based Forecasting, 2026–2034

• Forecast the market separately for carotid stenting, TAVR-related cerebral protection, coronary procedures, peripheral interventions, and other in-scope applications.
• Project future eligible procedure volumes using historical trends, patient demand, clinical practice, and relevant healthcare utilization indicators.
• Estimate future EPD adoption rates and ASPs for each application.
• Incorporate expected changes in product availability, device technology, physician preferences, pricing, and reimbursement.

Forecast Formula:

• Future EPD Market = Σ (Future Eligible Procedures × Future EPD Utilization Rate × Future ASP)

11. Market Growth Drivers and Technology Trends

• Assess the impact of an aging U.S. population, cardiovascular disease burden, carotid artery disease, stroke prevention, and growth in minimally invasive cardiovascular procedures.
• Evaluate changes in CAS and TAVR volumes, physician adoption of cerebral protection, and the introduction of new FDA-cleared or approved technologies.
• Examine improvements in debris capture, filter design, device deliverability, lower-profile systems, proximal protection technologies, and integrated stent-protection systems.
• Assess whether new technologies improve adoption, increase ASPs, or shift demand between competing products.
• Validate technology-related assumptions using clinical evidence, regulatory documentation, manufacturer announcements, and interviews with healthcare professionals.

12. Primary Research and Expert Interviews

• Conduct interviews with interventional cardiologists, vascular surgeons, interventional radiologists, structural heart specialists, hospitals, catheterization laboratories, neurointerventional centers, group purchasing organizations, distributors, and manufacturers.
• Collect information on:
  • Annual CAS and TAVR procedure volumes.
  • EPD utilization by application and clinical setting.
  • Average device acquisition prices and contractual discounts.
  • Preferred manufacturers and product technologies.
  • Peripheral procedures involving embolic protection.
  • Product adoption, substitution, and purchasing trends.
  • Expected utilization and pricing through 2030 and 2034.
• Use primary research to validate assumptions that cannot be reliably derived from public claims or manufacturer disclosures alone.

13. Epidemiology-Based Market Estimation

• Use disease prevalence and eligible patient populations as a secondary demand-based validation method.
• Estimate the population with relevant cardiovascular conditions, the proportion eligible for intervention, the intervention rate, and the proportion of procedures using EPDs.
• Avoid applying EPD adoption directly to the entire disease population, since only a subset of patients undergoes eligible procedures.

Formula:

• Epidemiology-Based EPD Market = Eligible Patient Population × Intervention Rate × EPD Adoption Rate × Average Selling Price per Device
• Reconcile this estimate with actual procedure volumes to account for repeat interventions, differences in eligibility, and variation in treatment patterns.

14. Historical Market Estimation

• Estimate historical market size using application-specific procedure volumes, EPD utilization rates, device shipments, and historical ASPs.
• Review changes in CAS and TAVR procedure volumes, cerebral protection adoption, product launches, regulatory clearances, pricing, and hospital purchasing practices.
• Apply consistent product definitions across historical years and account for changes in technology mix and market coverage.

Formula:

• Historical EPD Market Value = Historical Eligible Procedures × Historical EPD Utilization × Historical ASP

15. Geographic and Application-Level Segmentation

• Develop the national estimate by application and, where data permit, by state or healthcare region.
• Evaluate geographic differences in procedure volumes, specialist availability, hospital infrastructure, device adoption, and purchasing patterns.
• Segment the market by device type, clinical application, technology, manufacturer, and care setting.
• Ensure the sum of regional estimates reconciles with the national market total and that integrated systems are not counted in multiple categories.

16. Market Triangulation and Final Reconciliation

• Reconcile four independent estimation approaches:
  1. Procedure-based: Eligible procedures × EPD utilization × ASP.
  2. Claims-based: Claims-derived procedure volumes × estimated EPD utilization × ASP.
  3. Manufacturer-based: U.S. EPD units sold × average selling price.
  4. Epidemiology-based: Eligible patients × intervention rate × EPD adoption × ASP.
• Investigate discrepancies arising from differences in market scope, procedure coding, non-Medicare utilization, product availability, bundled pricing, inventory, and manufacturer revenue allocation.
• Avoid mechanically averaging the four estimates. Select the final market value based on the reliability, completeness, and consistency of the underlying evidence.

Final Market Formula:

• United States Embolic Protection Device Market = Carotid EPD Revenue + TAVR/Cerebral EPD Revenue + Coronary EPD Revenue + Peripheral EPD Revenue + Other In-Scope EPD Revenue
• Each application is estimated using: Market Revenue = Eligible Procedure Volume × EPD Utilization Rate × Average Selling Price
• The procedure-based approach should serve as the primary estimation method, with CMS claims, FDA product information, manufacturer sales, and epidemiological data providing independent validation.

Market Segmentations

Product

• Distal Filter Devices
• Distal Occlusion Devices
• Proximal Occlusion Devices

Application

• Coronary Artery Treatment
• Carotid Artery Treatment
• Others

Procedure

• Percutaneous Coronary Intervention
• Carotid Artery Stenosis
• Saphenous Vein Graft Intervention
• Aortic Valve Stenosis (Transcatheter Aortic Valve Replacement)
• Others

Material

• Nitinol
• Polyurethane
• Usage
• Disposable Devices
• Re-Usable Devices

End-User

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Others

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Abbott Laboratories
• Allium Medical Solutions Ltd.
• Boston Scientific Corporation
• Cardinal Health Inc.
• Edwards Lifesciences Corporation
• Medtronic Inc.
• Silk Road Medical Inc.

Report Details: